Despite the availability of modern diagnostic techniques and plethora of treatment options, the therapeutic outcome in patients suffering from different cancers is still not satisfactory. One of the key reasons for this sub-optimal outcome is heterogeneity, both at the genetic and epigenetic level, resulting in widely varied therapeutic responses between individual patients. To address this, it is essential that we adopt an individualised approach in studying cancer.

Patient Derived Organoid (PDO) models are relatively new type of 3D tissue culture system that recapitulate the key structural, functional and molecular aspects of the patient organs more closely than their 2D cell line counterparts. At the same time, these personalised ex vivo models are amenable for high throughput studies unlike the xenograft animal models.

Our group is currently invested in developing and exploiting PDO models of solid tumours to understand disease biology, identify alternative therapeutic targets and establish drug response profiling (DRP) platform with the aim of providing personalised treatment for cancer patients.

Note: Academic or industry groups who want to collaborate or partner with us are always welcome to discuss the possibilities. "Alone we can do so little; together we can do so much." – Helen Keller